•  
  •  
  •  
  •  

2026-05-20 23:00:00

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26

Keywords Selected:  CaplinPointLaboratories

Stock Report

  • Caplin Point Laboratories Ltd Q4 FY2026 consolidated PAT higher at Rs. 170.11 crores
  • Caplin Steriles Ltd gets USFDA approval for Calcium Gluconate Injection
  • Caplin Steriles gets USFDA approval for Potassium Phosphates Injection
  • Caplin Steriles gets USFDA approval for Desmopressin Acetate Injection
  • Caplin Steriles gets USFDA approval for Sodium Phosphates Injection
  • Caplin acquires 10 approves ANDAs injection and Opthalmic products
  • Caplin Point Laboratories Ltd's injectables facility completes INVIMA audit successfully
  • Caplin Steriles gets USFDA approval for Linezolid Injection, Infusion bags
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Caplin Point Laboratories Ltd's arm acquires land in Mexico
  • Caplin Point Laboratories Ltd consolidated Q2FY26 PAT up at Rs. 154.45 crores
  • Caplin Steriles Ltd receives USFDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection
  • Caplin Steriles Ltd granted final approval for ANDA Milrinone Lactate in 5% Dextrose Injection by USFDA
  • Caplin Point Laboratories Ltd Q1 FY2026 consolidated net profit up at Rs. 152.80 crores
  • Caplin Point Laboratories Limited declares interim dividend of Rs. 3
  • Caplin Point Laboratories Ltd Q4 FY2025 consolidated PAT climbs to Rs. 142.57 crores
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Haloperidol Decanoate Injection
  • Caplin Steriles Ltd gets USFDA approval for Phytonadione Injectable Emulsion
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
  • Caplin Steriles gets USFDA approval for Levetiracetam in Sodium Chloride Injection, Infusion Bags
  • Caplin Steriles gets USFDA approval for Difluprednate Ophthalmic Emulsion
  • Caplin Point Laboratories Ltd's consolidated net profit for Q2FY25 higher at Rs. 130.80 crores
  • ANVISA - Brazil completes inspection at Caplin Steriles' facility at Gummidipoondi
  • Caplin Steriles Ltd gets USFDA approval for Ephedrine Sulfate injection USP

Latest Post

  • GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
  • Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
  • Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • DevX - Standalone Revenue from Operations grew 34.3% YoY in FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025